Diagnosis and management of hypocalcaemiaBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39582.589433.BE (Published 05 June 2008) Cite this as: BMJ 2008;336:1298
- Mark S Cooper, senior lecturer and consultant endocrinologist,
- Neil J L Gittoes, senior lecturer and consultant endocrinologist
- Correspondence to: N J L Gittoes, Department of Endocrinology, Queen Elizabeth Hospital, Birmingham B15 2TH
Hypocalcaemia is a potentially life threatening biochemical abnormality that carries risks for serious errors in diagnosis and treatment. Hypocalcaemia presents in primary and secondary care; it has a prevalence of 18% in all patients in hospital and 85% in the intensive care unit.1 2 The most common cause of hypocalcaemia in primary care is vitamin D deficiency, which—depending on population demographics—may have a prevalence as high as 50%.3 Hypocalcaemia may be an asymptomatic laboratory finding or a life threatening metabolic disturbance. Acute hypocalcaemia can result in severe symptoms that require rapid admission to hospital and correction. In contrast, when hypocalcaemia develops slowly patients can be surprisingly free of symptoms. This review will help clinicians to optimise the diagnosis and management of patients with hypocalcaemia. Because hypocalcaemia often presents as an emergency and symptoms are rapidly reversed by giving calcium, the evidence base for managing acute hypocalcaemia is mostly based on experience rather than controlled trials.
Sources and selection criteria
We searched PubMed for articles whose titles included the terms “hypocalcaemia”, “hypoparathyroidism”, or “osteomalacia” and restricted the search to articles published in English in the previous 10 years. We individually reviewed the titles of the resulting 578 articles to identify major themes. Additional searches were made of contemporary textbooks.
Who gets hypocalcaemia and why?
The concentration of calcium in the serum (normal range 2.10-2.60 mmol/l)is regulated by the action of parathyroid hormone and vitamin D on the kidneys, bones, and gastrointestinal tract (fig 1)⇓. Parathyroid hormone stimulates calcium resorption in the kidney and calcium release from bone. It also stimulates renal production of 1,25-dihydroxyvitamin D (calcitriol) from 25-hydroxyvitamin D. 1,25-Dihydroxyvitamin D is the most active form of vitamin D, and it acts on the gastrointestinal tract to increase calcium absorption. Vitamin D is obtained mainly through synthesis in the skin, with a small contribution from the diet. Skin synthesis requires exposure to ultraviolet light and is reduced by skin pigmentation.
Hypocalcaemia with low vitamin D concentrations
Hypocalcaemia can occur in people whose exposure to ultraviolet light is low, especially those with a diet that is poor in vitamin D. Vitamin D requirements increase during and after pregnancy. Low maternal vitamin D concentrations are associated with hypocalcaemia in breastfed children.4
Hypocalcaemia caused by vitamin D deficiency is seen in some patients taking antiepileptic drugs, which induce enzymes that increase vitamin D metabolism.5 In a study of institutionalised children with poorly controlled epilepsy, the prevalence of vitamin D deficiency was 75%.6 Poor nutrition and minimal exposure to the sun probably contributed to the osteomalacia.
Patients with small intestinal disease—such as coeliac disease—where dietary calcium and vitamin D absorption are reduced, may also present with hypocalcaemia. Occasionally, hypocalcaemia is seen in people with a profoundly low dietary intake of calcium whose vitamin D concentrations are within the normal range.
Hypocalcaemia with reduced parathyroid hormone function
Hypocalcaemia occurs in patients with impaired function of the parathyroid glands. This is most common after thyroid or parathyroid surgery, but it can be idiopathic—mostly in young adults and less often as part of a genetic syndrome, such as autoimmune polyglandular syndrome type 1.7 Reduced concentrations of parathyroid hormone lead to excessive renal calcium loss and reduced intestinal absorption of calcium secondary to decreased production of 1,25-dihydroxyvitamin D. Occasionally, tissue resistance to parathyroid hormone can produce a biochemical pattern similar to hypoparathyroidism, even though concentrations of the hormone are high. Such “pseudohypoparathyroidism” is caused by failure of parathyroid hormone to activate its signalling pathways.8 Pseudohypoparathyroidism is a genetically heterogeneous condition, with some patients having skeletal abnormalities (Albright’s hereditary osteodystrophy; fig 2)⇓, that can occur in other family members independent of any abnormality of serum calcium. The presence of these features and normal calcium biochemistry is termed pseudopseudohypoparathyroidism.
Severe hypocalcaemia has been reported in patients with pre-existing vitamin D deficiency who receive intravenous bisphosphonates because these compounds block bone resorption.9 Table 1⇓ outlines common and less common causes of hypocalcaemia.
How does hypocalcaemia present in clinical practice?
Extracellular calcium concentrations are important for the normal functioning of muscles and nerves. Thus, classic symptoms of hypocalcaemia are neuromuscular excitability in the form of muscle twitching, spasms, tingling, and numbness. Carpopedal spasm is characteristic but in severe cases can progress to tetany, seizures, and cardiac dysrhythmias. In patients without overt signs, underlying neuromuscular excitability can become evident with provocation—tapping the parotid gland over the facial nerve can induce facial muscle spasm (Chvostek’s sign; fig 3)⇓. However, 10% of normal people have a positive Chvostek’s sign. Conversely, a small study of patients with hypoparathyroidism and biochemically confirmed hypocalcaemia found that 29% were negative for Chvostek’s sign, which makes this test a poor discriminator.10
Mild hypoxia induced by inflation of a blood pressure cuff can precipitate carpopedal spasm (Trousseau’s sign; fig 4)⇓. Trousseau’s sign is relatively specific for hypocalcaemia—94% of hypocalcaemic patients display a positive sign, compared with 1% of normocalcaemic people.10
The development of neuromuscular excitability depends on both the absolute concentration of calcium and how rapidly it falls. Rapid falls in calcium—for example, after the removal of a parathyroid adenoma—are often associated with symptoms, whereas patients who develop hypocalcaemia gradually can be surprisingly free of symptoms, and the diagnosis may only become evident as an incidental biochemical finding. Longstanding hypocalcaemia, even without neuromuscular symptoms, is associated with the development of neuropsychiatric symptoms,13 cataract formation, and occasionally raised intracranial pressure.14
What is clinically relevant hypocalcaemia?
The serum calcium concentration must be interpreted in relation to serum albumin. Serum calcium exists in an ionised form (∼50%) or is bound to albumin or other ions. Only ionised calcium is biologically important. Various factors alter the ratio of ionised calcium to bound calcium, but the most important factor is the albumin concentration. Many medical conditions cause a decrease in serum albumin. Serum calcium concentrations are therefore “corrected” to a reference albumin concentration of 40 g/l, and for every 1 g/l of albumin above or below this value, the calcium is adjusted by decreasing or increasing by 0.02 mmol/l.15 For example, a calcium concentration of 2.05 mmol/l with an albumin concentration of 35 g/l would be corrected to 2.15 mmol/l, which would correct the hypocalcaemic value to normal. This estimation is often used, but it can be unreliable in some situations, such as critical illness.16 If it is doubtful whether total calcium reflects ionised calcium, the ionised value can be checked directly. Other situations in which the assessment of serum calcium may be inappropriately low include recent use of certain gadolinium contrast agents and contamination of blood samples by EDTA.
Serum calcium concentrations must be interpreted in the context of serum albumin concentrations
Patients with a corrected calcium <1.9 mmol/l should be urgently assessed for admission, investigation, and treatment
Strong risk factors for vitamin D deficiency include pigmented skin, skin coverage, or both
In patients with low magnesium, hypocalcaemia is unlikely to be corrected without first correcting the low magnesium
Patients with parathyroid hormone deficiency need calcitriol or alfacalcidol rather than conventional doses of colecalciferol or ergocalciferol
Which tests help make the diagnosis and define the cause of hypocalcaemia?
If the cause of hypocalcaemia is not clinically obvious the most important investigation is to measure serum parathyroid hormone. A standard biochemical profile, a parathyroid hormone measurement, and the clinical history will usually provide the likely cause of hypocalcaemia. Figure 5⇓ shows an algorithm for investigating hypocalcaemia.
In true hypocalcaemia, parathyroid hormone concentrations should be high if the parathyroids are appropriately responding to the reduced negative feedback of calcium or low if these glands are the cause of the problem. “Normal” concentrations of parathyroid hormone in this context are inappropriate and thus abnormal. A high concentration of parathyroid hormone in the presence of normal renal function suggests deficiency of vitamin D or calcium malabsorption. A low concentration usually indicates hypoparathyroidism. Parathyroid hormone concentrations can be normal in hypoparathyroidism, but they are usually within the lower part of the reference range. Parathyroid hormone concentrations can also be inappropriately normal in hypomagnesaemia (see below) or when the extracellular calcium sensing receptor has increased sensitivity (an autosomal dominant genetic disorder).17
A raised serum alkaline phosphatase suggests osteomalacia as a result of vitamin D deficiency. The possibility of metastatic cancer, with sclerotic metastases causing rapid absorption of calcium into the skeleton, should also be excluded. Parathyroid hormone stimulates renal phosphate clearance, so serum phosphate should be low in non-parathyroid disease but high in parathyroid hormone deficiency. Measuring phosphate has limited value because it varies diurnally and is affected by food intake. Renal function should be measured because the kidney is central to several aspects of calcium homoeostasis.
Other tests may be needed in some situations. Serum 25-hydroxyvitamin D concentrations are useful in confirming vitamin D deficiency when it presents atypically, and it should be assessed in patients with possible pseudohypoparathyroidism. Serum magnesium is important for the synthesis and release of parathyroid hormone.18 In hypomagnesaemia, the release of parathyroid hormone is inhibited, leading to (potentially severe) hypocalcaemia. The prevalence of hypomagnesaemia in a large primary care cohort was 2%,19 but in intensive care it can be up to 65%.20 Poor nutrition associated with chronic alcohol use, prolonged diarrhoea, and treatment with diuretics and certain chemotherapeutics (such as cisplatin) causes hypomagnesaemia. Recognition of hypomagnesaemia is important because in this setting it is difficult to reverse hypocalcaemia without magnesium repletion.
Additional educational resources
Endotext online textbook (www.endotext.org/parathyroid/)—Website that covers a range of bone and mineral disorders
Osteoporosis and bone physiology. Osteomalacia (http://courses.washington.edu/bonephys/hypercalU/opmal2.html)—Educational website with resources relating to osteomalacia
Arthritis Research Campaign. Osteomalacia resources (www.arc.org.uk/arthinfo/)—Educational material on osteomalacia, including information sheets in a range of languages
How is hypocalcaemia treated?
The optimal management of hypocalcaemia has not been examined in clinical trials. A core of accepted practice exists, however. The approach to treatment depends on speed of onset, biochemical severity, and clinical features.
Acutely presenting hypocalcaemia
Neuromuscular irritability with hypocalcaemia requires prompt management in hospital and treatment with intravenous calcium. Asymptomatic patients with corrected serum calcium less than 1.9 mmol/l may develop serious complications and admission should be considered. Figure 6⇓ shows an algorithm for managing acute hypocalcaemia in adults that is based on clinical experience and expert recommendations.21 Calcium gluconate is the preferred form of intravenous calcium because calcium chloride is more likely to cause local irritation. One or two 10 ml ampoules of 10% calcium gluconate should be diluted in 50-100 ml of 5% dextrose and infused slowly over 10 minutes. Electrocardiographic monitoring is recommended because dysrhythmias can occur if correction is too rapid. Treatment can be repeated until symptoms have cleared. Often this offers only temporary relief, and continuous administration of a dilute solution of calcium may be needed to prevent recurrence of hypocalcaemia. Ten 10 ml ampoules of 10% calcium gluconate in 1 litre of 5% dextrose or 0.9% saline may be given at an initial infusion rate of 50 ml/hour, with the aim of maintaining serum calcium at the lower end of the reference range.21 An infusion of 10 ml/kg of this solution over four to six hours will increase serum calcium by 0.3-0.5 mmol/l. Oral calcium supplements should be given concurrently, and—if parathyroid hormone is deficient or non-functional—calcitriol should be given (for example, 1 μg/day).
What is the optimal long term treatment of hypoparathyroidism—active treatment with vitamin D or replacement of parathyroid hormone?
What is the best way to prevent vitamin D deficiency—dietary supplements, food fortification, or adequate sun exposure?
Do low concentrations of vitamin D predispose people to malignancy or inflammatory disease, as epidemiological studies suggest?
Patients taking digoxin have increased cardiac sensitivity to fluctuations in serum calcium, so intravenous calcium administration should be more cautious in this setting, with careful electrocardiographic monitoring. Patients with hypocalcaemia related to hypomagnesaemia will need magnesium replacement.
With milder degrees of hypocalcaemia, treatment depends on the underlying cause. In vitamin D deficiency, treatment should be with vitamin D, either ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3; these two forms of vitamin D can be considered identical in this setting). Most available vitamin D preparations include calcium, and two tablets of calcium with vitamin D, each containing 400 IU vitamin D, are usually given daily. This dose of vitamin D is relatively low, and patients with symptomatic vitamin D deficiency or those who fail to respond can be treated in the short term with higher doses, such as 50 000 IU orally once a week for eight weeks or 300 000 IU intramuscularly every three months.22
In patients with hypoparathyroidism, the above doses of vitamin D are ineffective because parathyroid hormone is needed for conversion to 1,25-dihydroxyvitamin D. Thus calcitriol or alfacalcidol is needed. Typical starting doses are 0.5 μg of calcitriol or 1 μg of alfacalcidol each day, with doses being increased every four to seven days to achieve a serum calcium in the lower part of the reference range. Once a stable calcium concentration is achieved, concentrations should be monitored every three to six months. The main long term risk is the development of nephrocalcinosis as a result of hypercalciuria. Urinary calcium excretion should be monitored annually and if high the dose of vitamin D may need to be reduced.
In hypocalcaemia caused by malabsorption, the underlying problem should be treated if possible. Patients with coeliac disease should receive calcium and vitamin D orally and should comply with a gluten free diet.23
Patients with hypocalcaemia need careful and timely assessment and intervention to ensure that the risk of life threatening complications is minimised. Where doubt exists and in symptomatic patients, urgent referral to secondary care for further investigation and treatment is required.
Contributors: NJLG and MSC both searched the literature. NJLG wrote the initial draft, which was further developed by both authors. The final version was approved by both authors. NJLG is guarantor.
Competing interests: None declared.
Provenance and peer review: Commissioned; externally peer reviewed.